查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2018112

动物用药品市场：2026-2032年全球市场预测（依产品类型、给药途径、目标动物、适应症、通路及最终用户划分）

Veterinary Pharmaceuticals Market by Product Type, Route of Administration, Animal Type, Indications, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年动物用药品市值为447.8亿美元，预计到2026年将成长至485.7亿美元，复合年增长率为8.70%，到2032年将达到803.1亿美元。

主要市场统计数据
基准年 2025 447.8亿美元
预计年份：2026年 485.7亿美元
预测年份 2032 803.1亿美元
复合年增长率 (%) 8.70%

透过全面捕捉和整合临床创新、监管压力和相关人员的优先事项，我们重新定义了兽药面临的策略挑战。

动物用药品产业正处于关键的转折点，随着科学进步、动物照护模式的转变以及监管的加强，产品研发、分销和推广方式正在发生根本性的变革。本导言概述了影响相关人员（包括製造商、兽医、动物健康网路和终端使用者）优先事项的关键因素。此外，本导言还着重分析了治疗方法创新、合理使用抗生素以及影响整个价值链决策的商业性动态之间的相互作用，从而提供了更广泛的视角。

生物技术、数位诊断和合理使用政策带来的策略性环境变化正在重塑发展、分销和投资重点。

从实验室到农场和诊所，一系列协同变化正在重塑产业格局。生物技术驱动的疫苗和新型抗菌药物正在重塑治疗路径，而数位健康工具和远端医疗对伴侣动物和牲畜的处方行为和用药依从性正产生日益显着的影响。这些技术进步缩短了诊断时间，实现了更精准的干预，改变了对传统频谱药物的需求模式，并将投资转向靶向性强、循证的产品。

2025 年关税调整将如何重塑整个兽药价值链的筹资策略、供应链在地化和商业环境？

2025年实施的关税调整的累积影响正在扩大整个动物医药系统在成本、供应链和策略采购方面的考量。製造商和经销商正在重新思考其筹资策略，以在确保能够从全球供应商获得关键活性药物成分、辅料和特殊包装的同时，降低关税相关的成本上涨。这种重新思考凸显了供应商多元化、关键生产流程近岸外包以及重新谈判商业条款的重要性，以在不影响品质或合规性的前提下维持获利能力。

透过对产品、目标动物物种、给药途径、适应症、分销管道和最终用户进行综合細項分析，可以製定有针对性的开发和商业化策略。

有效的市场区隔揭示了价值创造与临床需求的交集，有助于产品策略和销售管道的开发。从产品角度来看，市场涵盖药品、饲料药品和疫苗。药品细分包括镇痛药、感染疾病、抗发炎药和驱虫药。感染疾病又细分为抗生素和抗真菌药物，而抗发炎药则分为非类固醇类和类固醇类。驱虫药进一步分为体外驱虫药和体内驱虫药。药用饲料包括抗生素饲料、驱虫饲料、生长促进剂、营养饲料和益生菌/益生元饲料。疫苗细分基于平台和风险等级，将疫苗分为灭活疫苗和活病毒疫苗，每种疫苗对低温运输和监管的要求各不相同。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和细微的监管差异正在影响着进入、部署和供应链策略。

区域趋势因地域条件不同，对法律规范、供应链韧性和商业性机会的影响也各不相同。在美洲，先进的伴侣动物疗法的高渗透率、不断进步的兽医标准以及强大的零售和兽医分销网络加速了新配方的推广应用，从而推动了市场活跃度。由于区域内的交易行为和报销机制存在差异，製造商需要调整定价策略，并强调产品安全性和便利性，以满足宠物饲主和大型农场的需求。

透过整合研发、卓越的生产能力和策略伙伴关係，实现竞争差异化，加速生技药品和先进疗法的商业化。

该领域的竞争格局由大型跨国公司、专业生物技术公司和高度灵活的契约製造(CMO) 组成。主要企业凭藉其整合研发能力、先进製造技术和广泛商业网络的能力脱颖而出，从而实现生物製药和复杂製剂的快速规模化生产。策略联盟和授权协议十分普遍，尤其是在疫苗平台开发和新型抗寄生虫药物的化学设计方面，各企业力求利用专业技术供应商的技术来补充自身的技术优势。

采取切实可行的策略措施，协调研发重点、供应链韧性、管理以及数位化驱动的商业化，以建立永续的竞争优势。

产业领导企业必须将自身策略与两大基本要素──创新和供应链韧性──相契合，才能获得临床和商业性价值。优先发展标靶治疗和预防性生物製药的研发项目，并将合理的抗菌药物使用纳入产品标籤、行销和上市后监测活动，以满足监管和社会期望，至关重要。投资于能够提高患者依从性、减少给药频率和简化给药方式的製剂技术，将有助于临床医生和患者更好地接受这些疗法。

采用稳健的混合调查方法，结合与关键相关人员的访谈、科学文献综述、监管分析和供应链映射，以获得可操作的见解。

本分析采用多方面调查方法，以确保研究结果的稳健性，并将关键相关人员的见解与二手科学和监管文献进行交叉比对。主要研究活动包括对兽医、行业高管、生产合作伙伴和分销管道负责人进行结构化检验，以了解营运现状、未满足的需求和采购趋势。这些定性资讯与公开的监管文件、同行评审的科学论文和企业资讯披露相结合，用于检验治疗趋势并评估政策变化带来的实际影响。

一项旨在将科学进步转化为永续商业性成果的决定性整合，强调创新协调、管理整合和供应链重组。

总之，在生技药品和标靶治疗的创新、监管预期变化以及贸易调整和流通结构转变带来的商业性压力等因素的共同推动下，动物用药品产业正经历着一场意义深远的变革。这些因素共同要求企业在产品设计、证据产生和供应链建构方面采取更具策略性的方法。那些积极实践管理原则、投资开发有助于提升合规性的产品并建立能够抵御关税波动影响的采购体系的企业，将更有能力在满足临床医生和饲主期望的同时，维持利润率。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：动物用药品市场：依产品类型划分

  • 製药
    • 止痛药
    • 抗感染药物
      • 抗生素
      • 抗真菌药物
      • 抗病毒药物
    • 抗发炎药
      • NSAIDs
      • 皮质类固醇
    • 杀虫剂
    • 麻醉剂
    • 镇静剂
  • 药用饲料添加剂
  • 疫苗
    • 灭活疫苗
    • 减毒活病毒疫苗
    • 重组疫苗

第九章：动物用药品市场：依给药途径划分

  • 注射药物
    • 肌肉内部
    • 皮下
  • 口服
    • 咀嚼片
    • 悬浮液/糖浆
    • 药片
  • 外用
    • 喷
    • 粉末
    • 软膏

第十章：动物用药品市场：依动物类型划分

  • 伴侣动物
    • 猫
    • 狗
    • 马
  • 家畜
    • 牛
    • 家禽
    • 绵羊/山羊
    • 猪

第十一章：动物用药品市场依适应症划分

  • 慢性疼痛和急性疼痛管理
  • 免疫系统疾病
  • 感染疾病
  • 代谢性疾病
  • 神经系统疾病
  • 整形外科疾病
  • 寄生虫感染疾病
  • 生殖健康

第十二章：动物用药品市场：依通路划分

  • 在线的
  • 离线

第十三章：动物用药品市场：依最终用户划分

  • 畜牧场
  • 宠物饲主
  • 兽医医院和诊所

第十四章动物用药品市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：动物用药品市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章动物用药品市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国动物用药品市场

第十八章：中国动物用药品市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aurora Pharmaceutical, Inc.
  • Biogenesis Bago SA
  • Biovac Ltd.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Chanelle Pharma
  • China Animal Husbandry Industry Co., Ltd.
  • Dechra Pharmaceuticals PLC
  • ECO Animal Health Group PLC
  • Elanco Animal Health Incorporated
  • Heska Corporation by Mars, Incorporated
  • Hester Biosciences Limited
  • Indian Immunologicals Ltd.
  • Intas Pharmaceuticals Ltd.
  • Laboratorio Drag Pharma Chile Invetec SA
  • Merck & Co., Inc.
  • Neogen Corporation
  • Norbrook Group
  • Phibro Animal Health Corporation
  • Teknofarma Srl
  • Vetoquinol Group
  • Vetpharma Animal Health SL by Insud Pharma SLU
  • Virbac SA
  • Zendal Group
  • Zoetis Inc.
Product Code: MRR-032F197B035E

The Veterinary Pharmaceuticals Market was valued at USD 44.78 billion in 2025 and is projected to grow to USD 48.57 billion in 2026, with a CAGR of 8.70%, reaching USD 80.31 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 44.78 billion
Estimated Year [2026] USD 48.57 billion
Forecast Year [2032] USD 80.31 billion
CAGR (%) 8.70%

Comprehensive framing of clinical innovation, regulatory pressures, and stakeholder priorities that together redefine strategic imperatives in veterinary pharmaceuticals

The veterinary pharmaceuticals sector stands at a pivotal juncture where scientific progress, evolving animal care paradigms, and heightened regulatory scrutiny converge to redefine how products are developed, distributed, and deployed. This introduction synthesizes the critical forces that are shaping stakeholder priorities across manufacturers, veterinarians, animal health networks, and end users. It frames the broader context by emphasizing the interplay between therapeutic innovation, antimicrobial stewardship, and commercial dynamics that influence decision-making across the value chain.

Emerging therapeutic modalities, such as precision antiparasitics, refined vaccine platforms, and formulations tailored to compliance in companion animals, are challenging legacy product portfolios and operational models. Concurrently, payers and procurement channels are demanding clearer evidence of clinical value and safety, while regulatory authorities are tightening oversight on residues and risk mitigation. These pressures are creating both constraints and opportunities: companies focused on targeted indication development, improved delivery systems, and integrated services are best positioned to meet shifting clinical expectations. Throughout this introduction, the emphasis remains on understanding how technological advances and policy shifts interact to create near-term strategic imperatives for industry participants.

Strategic landscape shifts driven by biotechnology, digital diagnostics, and stewardship policies that are reconfiguring development, distribution, and investment priorities

The landscape is being transformed by a suite of converging shifts that extend from the laboratory to the farm and the clinic. Biotechnology-enabled vaccines and novel antimicrobial alternatives are reshaping therapeutic pathways, while digital health tools and telemedicine increasingly influence prescribing behavior and adherence across companion and livestock populations. These technological advances reduce time to diagnosis and enable more precise interventions, thereby altering demand patterns for traditional broad-spectrum drugs and shifting investment toward targeted, evidence-backed products.

At the same time, regulatory and societal emphasis on antimicrobial stewardship is accelerating the adoption of medicated-feed alternatives, biologics, and preventive strategies, prompting manufacturers to reformulate pipelines and revisit lifecycle strategies. Market participants are also contending with evolving procurement channels as online pharmacies and integrated veterinary services gain traction, driving new distribution and commercialization models. Financial sponsors and strategic partners are prioritizing companies that demonstrate robust data packages, scalable manufacturing, and agility in supply chain management. In sum, the most consequential shifts are technological maturation, regulatory tightening, channel evolution, and investor preference for data-driven, scalable asset portfolios.

How 2025 tariff adjustments are reshaping sourcing strategies, supply chain localization, and commercial terms across the veterinary pharmaceuticals value chain

The cumulative impact of tariff adjustments introduced in 2025 has amplified cost, supply chain, and strategic sourcing considerations across the veterinary pharmaceuticals ecosystem. Manufacturers and distributors are recalibrating procurement strategies to mitigate tariff-related cost inflation while preserving access to critical active pharmaceutical ingredients, excipients, and specialized packaging sourced from global suppliers. This recalibration is prompting a renewed emphasis on supplier diversification, nearshoring of critical manufacturing steps, and renegotiation of commercial terms to maintain margin stability without compromising quality or regulatory compliance.

These fiscal headwinds also affect downstream stakeholders, including veterinary clinics and animal farms, which face pressure to optimize inventory and prioritize high-value interventions. In response, companies are accelerating investments in local manufacturing partnerships and contract development and manufacturing organizations that can offer tariff-resilient supply chains. Simultaneously, longer-term strategic responses include redesigning product portfolios to reduce reliance on tariff-exposed inputs and increasing collaboration with regional partners to streamline customs processes and compliance documentation. Collectively, these measures reduce exposure to future trade shocks and support continuity of therapeutic availability for both companion animals and livestock populations.

Integrated segmentation analysis across products, species, administration modes, indications, channels, and end users to inform targeted development and commercialization strategies

Effective segmentation reveals where value creation and clinical need intersect, informing product strategy and channel deployment. When examined by product, the market encompasses Drugs, Medicinal Feed, and Vaccines. Within Drugs, subcategories include Analgesics, Anti-Infectives, Anti-Inflammatories, and Parasiticides, and the anti-infective category further differentiates into Antibiotics and Antifungals while anti-inflammatory therapies separate into Non-Steroidal and Steroidal approaches; parasiticide treatments divide into Ectoparasiticides and Endoparasiticides. Medicinal Feed covers antibiotic medicated feed, antiparasitic medicated feed, growth promoters, nutritional medicated feed, and probiotic and prebiotic medicated feed. Vaccine segmentation is driven by platform and risk profile, distinguishing between inactivated vaccines and live vaccines, each with distinct cold-chain and regulatory implications.

Segmenting by animal type clarifies demand drivers and regulatory pathways, with Companion Animals split into Cats, Dogs, and Horses and Livestock Animals encompassing Cattle, Poultry, Sheep and Goats, and Swine, each species presenting unique therapeutic needs and administration practices. Mode of administration further influences formulation strategy, where Injectable routes include intramuscular and subcutaneous delivery, Oral forms cover capsules, liquid suspensions and syrups, and tablets, and Topical products are formulated as creams, lotions, and ointments; administration mode affects adherence, required caregiver skill, and product stability. Indication-based segmentation highlights focus areas such as chronic and acute pain management, immunological conditions, infectious diseases, metabolic and neurological disorders, orthopedic conditions, parasitic infections, and reproductive health, guiding clinical evidence generation and label claims. Distribution channels span online pharmacies, retail pharmacies, and veterinary clinics, each with different purchasing behaviors and regulatory obligations, while end users consist of animal farms, pet owners, and veterinary hospitals, informing pricing, packaging, and support services. Integrating these segmentation layers enables more precise targeting of R&D investments, commercialization plans, and post-market surveillance strategies.

Regional dynamics and regulatory nuances across the Americas, Europe Middle East Africa, and Asia-Pacific that determine access, adoption, and supply chain strategies

Regional dynamics shape regulatory frameworks, supply chain resilience, and commercial opportunity in distinct ways across geographies. In the Americas, market activity is driven by high adoption rates of advanced therapeutics in companion animals, progressive veterinary practice standards, and a robust network of retail and clinic-based distribution that accelerates uptake of novel formulations. Transactional behaviors and reimbursement nuances vary within the region, prompting manufacturers to adapt pricing strategies and to emphasize product safety and convenience for pet owners and large-scale farms alike.

Europe, the Middle East & Africa combine rigorous regulatory environments with diverse market maturities. Established European markets emphasize antimicrobial stewardship, stringent residue controls, and strong public sector engagement in livestock health, while markets in the Middle East and Africa present both growth opportunities and logistical complexities, including variability in cold-chain infrastructure and differing import regulations. Asia-Pacific is characterized by rapid modernization of livestock operations, intensifying demand for preventive vaccines and medicated feed solutions, and a growing companion animal segment with rising willingness to invest in advanced therapeutics. Supply chain considerations and local manufacturing partnerships play a pivotal role in all regions, and regulatory harmonization efforts, where they exist, materially influence market entry strategies and product lifecycle management.

Competitive differentiation through integrated R&D, manufacturing excellence, and strategic partnerships that accelerate biologics and advanced therapeutic commercialization

Competitive positioning in the sector reflects a mix of large multinational players, specialized biotechnology firms, and agile contract manufacturers. Leading companies differentiate through integrated capabilities that combine R&D strength, advanced manufacturing, and broad commercial networks, enabling rapid scale-up of biologics and complex formulations. Strategic alliances and licensing agreements are common as organizations seek to complement in-house expertise with niche technology providers, particularly in vaccine platform development and novel antiparasitic chemistries.

Innovation is increasingly financed through targeted partnerships, where larger firms provide capital and commercialization pathways while smaller entities supply scientific novelty. Companies that invest in digital tools for adherence monitoring, telehealth-enabled prescribing, and data-driven pharmacovigilance strengthen relationships with veterinarians and animal owners. Operational excellence in cold-chain logistics, regulatory affairs, and manufacturing quality is a persistent differentiator, as is the ability to demonstrate robust clinical evidence and stewardship frameworks. Overall, the competitive landscape rewards firms that combine scientific innovation with disciplined commercialization and supply chain resilience.

Practical strategic actions to align R&D focus, supply chain resilience, stewardship, and digital-enabled commercialization for sustainable competitive advantage

Industry leaders should align strategy with the twin imperatives of innovation and supply chain resilience to capture clinical and commercial value. Prioritize development programs that emphasize targeted therapeutics and preventative biologics, while embedding antimicrobial stewardship into labeling, marketing, and post-market surveillance activities to satisfy regulatory and societal expectations. Investing in formulation technologies that improve patient adherence, reduce dosing frequency, and simplify administration will drive uptake among clinicians and owners alike.

Simultaneously, reconfigure sourcing strategies to reduce tariff exposure and build redundancy through diversified supplier networks and regional manufacturing partnerships. Strengthen commercialization by integrating digital engagement platforms with traditional distribution channels to support telemedicine workflows, adherence monitoring, and data collection that bolster real-world evidence generation. Pursue collaborations and licensing models to accelerate access to novel platforms, while deploying rigorous pharmacovigilance and quality systems to maintain trust across stakeholders. Finally, tailor market entry plans to regional regulatory environments and species-specific needs to ensure alignment between clinical value propositions and local practice patterns.

Robust mixed-methods methodology combining primary stakeholder interviews, scientific literature review, regulatory analysis, and supply chain mapping to ensure actionable insights

The research methodology underpinning this analysis combined a multifaceted approach to ensure robustness, triangulating primary stakeholder insights with secondary scientific and regulatory literature. Primary engagements included structured interviews with veterinarians, industry executives, manufacturing partners, and distribution channel leaders to capture operational realities, unmet clinical needs, and procurement dynamics. These qualitative inputs were synthesized with public regulatory documents, peer-reviewed scientific studies, and corporate disclosures to validate therapeutic trends and to assess the practical implications of policy shifts.

Analytical steps included segmentation mapping across product types, species, administration routes, indications, distribution channels, and end users, enabling granular interpretation of where clinical demand aligns with commercial opportunity. Supply chain analysis focused on sourcing exposures, tariff impacts, and manufacturing capacity constraints. Finally, competitive assessment prioritized capabilities in R&D, manufacturing, regulatory affairs, and digital engagement. Throughout the methodology, care was taken to ensure transparency of assumptions and to corroborate findings through multiple independent sources, enhancing confidence in the conclusions and recommendations presented.

Conclusive synthesis emphasizing innovation alignment, stewardship integration, and supply chain redesign to translate scientific advances into durable commercial outcomes

In conclusion, the veterinary pharmaceuticals sector is navigating a period of substantive change driven by innovation in biologics and targeted therapeutics, evolving regulatory expectations, and commercial pressures stemming from trade adjustments and shifting distribution dynamics. These factors collectively require companies to be more strategic in product design, evidence generation, and supply chain configuration. Firms that proactively integrate stewardship principles, invest in formulating products that enhance compliance, and establish tariff-resilient sourcing will be better positioned to meet clinician and owner expectations while preserving operational margins.

The path forward involves a balanced approach: accelerate development of vaccines and targeted antiparasitics that reduce reliance on broad-spectrum antimicrobials, modernize manufacturing and logistics to mitigate trade-related disruptions, and adopt digital tools that enhance clinical decision-making and adherence. By aligning innovation priorities with regional regulatory nuances and end-user behaviors, organizations can translate scientific advances into durable commercial outcomes and improved animal health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Pharmaceuticals Market, by Product Type

  • 8.1. Drugs
    • 8.1.1. Analgesics
    • 8.1.2. Anti-Infectives
      • 8.1.2.1. Antibiotics
      • 8.1.2.2. Antifungals
      • 8.1.2.3. Antivirals
    • 8.1.3. Anti-Inflammatories
      • 8.1.3.1. NSAIDs
      • 8.1.3.2. Corticosteroids
    • 8.1.4. Parasiticides
    • 8.1.5. Anaesthetics
    • 8.1.6. Anesthetic
  • 8.2. Medicated Feed Additives
  • 8.3. Vaccines
    • 8.3.1. Inactivated Vaccines
    • 8.3.2. Live Attenuated Vaccines
    • 8.3.3. Recombinant Vaccines

9. Veterinary Pharmaceuticals Market, by Route of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Subcutaneous
  • 9.2. Oral
    • 9.2.1. Chews
    • 9.2.2. Liquid Suspension & Syrup
    • 9.2.3. Tablets
  • 9.3. Topical
    • 9.3.1. Sprays
    • 9.3.2. Powders
    • 9.3.3. Ointments

10. Veterinary Pharmaceuticals Market, by Animal Type

  • 10.1. Companion Animals
    • 10.1.1. Cats
    • 10.1.2. Dogs
    • 10.1.3. Horses
  • 10.2. Livestock Animals
    • 10.2.1. Cattle
    • 10.2.2. Poultry
    • 10.2.3. Sheep & Goats
    • 10.2.4. Swine

11. Veterinary Pharmaceuticals Market, by Indications

  • 11.1. Chronic & Acute Pain Management
  • 11.2. Immunological Conditions
  • 11.3. Infectious Diseases
  • 11.4. Metabolic Disorders
  • 11.5. Neurological Disorders
  • 11.6. Orthopedic Disorders
  • 11.7. Parasitic Infections
  • 11.8. Reproductive Health

12. Veterinary Pharmaceuticals Market, by Distribution Channel

  • 12.1. Online
  • 12.2. Offline

13. Veterinary Pharmaceuticals Market, by End User

  • 13.1. Animal Farms
  • 13.2. Pet Owners
  • 13.3. Veterinary Hospitals & Clinics

14. Veterinary Pharmaceuticals Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Veterinary Pharmaceuticals Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Veterinary Pharmaceuticals Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Veterinary Pharmaceuticals Market

18. China Veterinary Pharmaceuticals Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Aurora Pharmaceutical, Inc.
  • 19.6. Biogenesis Bago S.A.
  • 19.7. Biovac Ltd.
  • 19.8. Boehringer Ingelheim International GmbH
  • 19.9. Ceva Sante Animale
  • 19.10. Chanelle Pharma
  • 19.11. China Animal Husbandry Industry Co., Ltd.
  • 19.12. Dechra Pharmaceuticals PLC
  • 19.13. ECO Animal Health Group PLC
  • 19.14. Elanco Animal Health Incorporated
  • 19.15. Heska Corporation by Mars, Incorporated
  • 19.16. Hester Biosciences Limited
  • 19.17. Indian Immunologicals Ltd.
  • 19.18. Intas Pharmaceuticals Ltd.
  • 19.19. Laboratorio Drag Pharma Chile Invetec S.A.
  • 19.20. Merck & Co., Inc.
  • 19.21. Neogen Corporation
  • 19.22. Norbrook Group
  • 19.23. Phibro Animal Health Corporation
  • 19.24. Teknofarma S.r.l.
  • 19.25. Vetoquinol Group
  • 19.26. Vetpharma Animal Health S.L. by Insud Pharma S.L.U.
  • 19.27. Virbac S.A.
  • 19.28. Zendal Group
  • 19.29. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY PHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES VETERINARY PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA VETERINARY PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANAESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANAESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANAESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANESTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANESTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANESTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY RECOMBINANT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY RECOMBINANT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHEWS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHEWS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHEWS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORTHOPEDIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORTHOPEDIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORTHOPEDIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)